$60M B round to propel Landos through Phase II IBD trials

Landos' $60 million series B will enable it to complete two Phase II trials, one each in ulcerative colitis and Crohn's disease, of lead product BT-11.

Chairman, President and CEO Josep Bassaganya-Riera told BioCentury he expects the funding to last Landos Biopharma Inc. (Blacksburg,

Read the full 430 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE